Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Liabilities and Shareholders Equity (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $36.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 101.44% to $36.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.2 million, a 5.69% increase, with the full-year FY2025 number at $28.6 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $36.6 million for Q4 2025 at Neuphoria Therapeutics, up from $27.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $46.8 million in Q2 2022 to a low of $18.2 million in Q4 2024.
  • A 4-year average of $30.0 million and a median of $28.7 million in 2025 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 38.56% in 2023, then surged 101.44% in 2025.
  • Neuphoria Therapeutics' Liabilities and Shareholders Equity stood at $46.8 million in 2022, then plummeted by 38.56% to $28.7 million in 2023, then crashed by 36.79% to $18.2 million in 2024, then skyrocketed by 101.44% to $36.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Liabilities and Shareholders Equity are $36.6 million (Q4 2025), $27.3 million (Q3 2025), and $28.6 million (Q2 2025).